A tool for patients to use with their health care providers to help them decide what opioid agonist therapy (OAT) option would be best for them: sublingual buprenorphine (Suboxone), depot buprenorphine (Sublocade), methadone, or slow-release oral morphine (Kadian).
Authors: Karan Cheema, Meldon Kahan, Jason Rodgers, Ashley Smoke, Suzanne Turner, Jennifer Wyman, Maria Zhang
Reviewers: Lisa Bromley, Katie Dunham, Caryn Green, Janelle Hannon, Christina Henry, Cassandra Huck, Laura Jones, Kate Lazier, Andrew McLeod, Charlotte Munro, Patrick Nowak, Lori Regenstreif, Michael Roach, Elizabeth Shouldice, Anita Srivastava
Design: Brent Logan
Version date: 01 November 2023
A plain-language summary of the document “Recommendations for the use of slow-release oral morphine as opioid agonist therapy”, intended for patients interested in learning about slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).
Authors: Karan Cheema, Meldon Kahan, Jason Rodgers, Ashley Smoke, Suzanne Turner, Jennifer Wyman, Maria Zhang
Reviewers: Lisa Bromley, Katie Dunham, Caryn Green, Janelle Hannon, Christina Henry, Cassandra Huck, Laura Jones, Kate Lazier, Andrew McLeod, Charlotte Munro, Patrick Nowak, Lori Regenstreif, Michael Roach, Elizabeth Shouldice, Anita Srivastava
Design: Brent Logan
Version date: 01 November 2023
Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).
Authors: Karan Cheema, Meldon Kahan, Jason Rodgers, Ashley Smoke, Suzanne Turner, Jennifer Wyman, Maria Zhang
Reviewers: Lisa Bromley, Katie Dunham, Caryn Green, Janelle Hannon, Christina Henry, Cassandra Huck, Laura Jones, Kate Lazier, Andrew McLeod, Charlotte Munro, Patrick Nowak, Lori Regenstreif, Michael Roach, Elizabeth Shouldice, Anita Srivastava
Design: Brent Logan
Version date: 01 November 2023